Literature DB >> 25582099

Recurrence of high-grade cervical abnormalities following conservative management of cervical intraepithelial neoplasia grade 2.

Tom M Wilkinson1, Peter H H Sykes2, Bryony Simcock2, Simone Petrich3.   

Abstract

OBJECTIVE: Conservative management of cervical intraepithelial neoplasia (CIN) grade 2 in women younger than 25 years may reduce overtreatment. However, long-term efficacy remains uncertain. This retrospective cohort study aimed to determine the rate of recurrence of high-grade abnormalities among young women with a history of CIN 2 that spontaneously regressed within 2 years and compare this with the rate of high-grade abnormality in similar women with an initial diagnosis of CIN 1. STUDY
DESIGN: We identified all women aged younger than 25 years who were diagnosed with CIN 1 or CIN 2 between January 2005 and August 2009 within 2 colposcopy units. Follow-up data from the National Cervical Screening Programme were obtained to identify those women who developed recurrent high-grade lesions before October 2012. Comparisons were made using Cox proportional hazards regression.
RESULTS: A total of 683 women were included: 106 with CIN 2 that spontaneously regressed, 299 with treated CIN 2, and 278 with conservatively managed CIN 1. Median follow-up was 4 years. There was no significant difference in the risk of development of high-grade abnormalities after 2 years between the spontaneously regressing CIN 2 and CIN 1 groups (P = .83). Women with treated CIN 2 had a significantly lower risk of recurrence than women with untreated CIN 2 (P = .01).
CONCLUSION: CIN 2 that has spontaneously regressed appears to behave as a low-grade lesion. This study contributes to the growing body of evidence that careful observation of CIN 2 is an efficacious and appropriate initial management option for women aged younger than 25 years at diagnosis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cervical intraepithelial neoplasia; conservative management; grade 2; young women

Mesh:

Year:  2015        PMID: 25582099     DOI: 10.1016/j.ajog.2015.01.010

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Mass spectrometry and multivariate analysis to classify cervical intraepithelial neoplasia from blood plasma: an untargeted lipidomic study.

Authors:  Ana C O Neves; Camilo L M Morais; Thais P P Mendes; Boniek G Vaz; Kássio M G Lima
Journal:  Sci Rep       Date:  2018-03-02       Impact factor: 4.379

2.  Comparison of Expectant and Excisional/Ablative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in the Era of HPV Testing.

Authors:  Kevin Dominique Tjandraprawira; Adeola Olaitan; Aviva Petrie; Nafisa Wilkinson; Adam N Rosenthal
Journal:  Obstet Gynecol Int       Date:  2022-03-24

Review 3.  Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis.

Authors:  Karoliina Tainio; Antonios Athanasiou; Kari A O Tikkinen; Riikka Aaltonen; Jovita Cárdenas; Sivan Glazer-Livson; Maija Jakobsson; Kirsi Joronen; Mari Kiviharju; Karolina Louvanto; Sanna Oksjoki; Riikka Tähtinen; Seppo Virtanen; Pekka Nieminen; Maria Kyrgiou; Ilkka Kalliala
Journal:  BMJ       Date:  2018-02-27

4.  Outcomes of Conservative Management of High Grade Squamous Intraepithelial Lesions in Young Women.

Authors:  Marette H Lee; Sarah J Finlayson; Ksenia Gukova; Gillian Hanley; Dianne Miller; Leslie Ann Sadownik
Journal:  J Low Genit Tract Dis       Date:  2018-07       Impact factor: 1.925

5.  Conservative management of women with cervical intraepithelial neoplasia grade 2 in Denmark: a cohort study.

Authors:  M Skorstengaard; E Lynge; J Suhr; G Napolitano
Journal:  BJOG       Date:  2020-01-22       Impact factor: 6.531

6.  The role of EP-2 receptor expression in cervical intraepithelial neoplasia.

Authors:  Elisa Schmoeckel; Patricia Fraungruber; Christina Kuhn; Udo Jeschke; Sven Mahner; Theresa Maria Kolben; Thomas Kolben; Theresa Vilsmaier; Anna Hester; Helene Hildegard Heidegger
Journal:  Histochem Cell Biol       Date:  2020-08-26       Impact factor: 4.304

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.